Wegovy
Wegovy is a weight loss injection for adults dealing with obesity or weight-related health challenges. It contains semaglutide, a medication that mimics a natural hormone (GLP-1) to reduce appetite, increase feelings of fullness, and support effective weight loss when combined with a healthy diet and exercise Clinically proven to help patients lose up to 15% of their body weight, Wegovy is taken once a week via a simple injection. It's quickly becoming one of the most sought-after weight loss injections for those struggling with traditional weight loss methods. Wegovy is not yet available in New Zealand. *The image is representative only and may not reflect the packaging eventually available in New Zealand.
Book Now
What is Wegovy?
Wegovy is GLP-1 receptor agonists – they mimic your body’s natural GLP-1 hormone, which lowers blood sugar levels, slows digestion, and helps you feel full after eating.
Wegovy is semaglutide (similar to Ozempic). Weight loss via injectable diabetes medications of around 5% to 15% is typical for patients on Wegovy.
Weight loss medications are not suitable for everyone. What are the side effects of Wegovy?
There are also side effects associated with Wegovy and other injectable weight-loss medications. Weight loss injections may cause gastrointestinal problems, headache, fatigue and dizziness.
It’s important to know that these weight loss injections are not suitable for everybody. They are not recommended for people with certain medical conditions, medications or family history. Weight management strategies vary, and need to be customised to fit your circumstances.
Are these available as weight loss pills?
At the moment, GLP-1 medications are only available as weight loss injections, but not as weight loss pills.
References
1. Caterson ID, et al. Diabetes Obes Metab. 2019; 21(8): 1914-1924 and supplementary appendix.
2. Consumer Medicine Information.
3. Sumithran P, et al. N Engl J Med. 2011; 365(17): 1597-1604.
4. Suzuki K, Jayasena CN, Bloom SR. Exp Diabetes Res. 2012; 2012: 824303.
5. Sumithran P, Proietto J. Clin Sci (Lond). 2013; 124(4): 231-241.
6. Saxenda® New Zealand Data Sheet.
7. Rosenbaum M, Leibel RL. Int J Obes (Lond). 2010; 34(Suppl 1): S47-S55.
8. Pi-Sunyer X, et al. N Engl J Med. 2015; 373(1): 11–22, and supplementary appendix.
9. le Roux CW, et al. Lancet. 2017; 389: 1399-1409 and supplementary appendix.
10. Wharton S, et al. Postgrad Med. 2022; 134(1):14-19.
1. Caterson ID, et al. Diabetes Obes Metab. 2019; 21(8): 1914-1924 and supplementary appendix.
2. Consumer Medicine Information.
3. Sumithran P, et al. N Engl J Med. 2011; 365(17): 1597-1604.
4. Suzuki K, Jayasena CN, Bloom SR. Exp Diabetes Res. 2012; 2012: 824303.
5. Sumithran P, Proietto J. Clin Sci (Lond). 2013; 124(4): 231-241.
6. Saxenda® New Zealand Data Sheet.
7. Rosenbaum M, Leibel RL. Int J Obes (Lond). 2010; 34(Suppl 1): S47-S55.
8. Pi-Sunyer X, et al. N Engl J Med. 2015; 373(1): 11–22, and supplementary appendix.
9. le Roux CW, et al. Lancet. 2017; 389: 1399-1409 and supplementary appendix.
10. Wharton S, et al. Postgrad Med. 2022; 134(1):14-19.
